Executive interview – CytoDyn

Published on 15 April 2019

CytoDyn is on the cusp of potentially garnering its first FDA approval for its lead drug, Leronlimab (PRO 140) in HIV. In this video, the CEO and chief medical officer discuss how the company reached this point and what’s next, including a potentially transformative pipeline of opportunities in metastatic cancer, also now in development.

Share this with friends and colleagues